NRIX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nurix Therapeutics Inc (NRIX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has strong positive catalysts, including significant institutional buying, favorable analyst ratings, and a promising pipeline. Despite the pre-market dip, the technical indicators and options data do not suggest significant downside risk, making this a solid entry point for long-term growth.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 54.243, suggesting no overbought or oversold conditions. The stock is trading near its pivot level of 15.761, with resistance at 16.307 and support at 15.214. Moving averages are converging, showing a potential consolidation phase.
Redmile Group's significant acquisition of 4.4 million shares, increasing its stake to 11.31%, indicates strong institutional confidence. Analysts have raised price targets across the board, with Piper Sandler, Stifel, and H.C. Wainwright setting targets at $35, $35, and $32, respectively. The company's pipeline, particularly the bexobrutideg trials, shows promising growth potential.
The pre-market price is down 0.43%, and there are no immediate clinical catalysts expected in 2026, which may limit short-term price movement. Additionally, the stock has a 60% chance of declining 6.23% over the next month based on historical patterns.
In Q4 2025, revenue increased by 2.21% YoY to $13.58 million. Net income improved by 33.60% YoY but remains negative at -$78.22 million. EPS increased by 9.33% YoY to -0.82. Gross margin remains at 100%, indicating efficient cost management despite losses.
Analysts are overwhelmingly positive, with multiple firms maintaining Overweight or Buy ratings and raising price targets. Morgan Stanley upgraded the stock to Overweight with a target of $36, citing higher probability of success for its pipeline and potential growth opportunities.
